• Psyched Wellness (PSYC) will begin accepting pre-orders for Calm on July 19, with products anticipated to reach consumers in the U.S. in the fall
  • Calm, the company’s flagship product, is the first legal Amanita Muscaria mushroom extract approved for sale in the U.S.
  • Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products
  • Psyched Wellness Ltd. (PSYC) is down 4.17 per cent on the day, trading at C$0.115 per share at 11:30 am ET

Psyched Wellness (PSYC) will begin accepting pre-orders for Calm on July 19.

Products are anticipated to reach consumers in the U.S. in the fall.

Calm, the company’s flagship product, is the first legal Amanita Muscaria mushroom extract approved for sale in the U.S. It does not require a prescription, leaving the retail landscape open to many possibilities for distribution and listing potential.

Jeffrey Stevens, CEO of Psyched Wellness, commented on the announcement.

“With today being Psyched Wellness’ 2nd anniversary as a company, we felt it was perfect timing to set a date for consumers in the United States to be able to pre-order Calm.”

He added,

“It has been a long journey to get to this point, and I would like to take this opportunity to thank my co-founder, David Shisel, our team, KGK Science and Vantage Hemp for all of their hard work and commitment to get us to where we are today. The most exciting part for me is that we have just scratched the surface with respect to potential uses and delivery forms for AME-1. Stay tuned for more to come from Psyched.”

Psyched Wellness is a health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods.

Psyched Wellness Ltd. (PSYC) is down 4.17 per cent on the day, trading at C$0.115 per share at 11:30 am ET.

More From The Market Online

Psychedelic stock begins take-home LSD microdosing clinical trial

MindBio Therapeutics (CSE:MBIO) secures approvals for MB22001 – a form of LSD – microdosing use by patients in a controlled clinical trial.

Red Light Holland begins experimental research on psilocybin truffles

Red Light Holland has revealed that it has officially begun an experimental research project on its psilocybin truffles.
MindBio Therapeutics chief executive officer Justin Hanka.

Psychedelic stock clears hurdle to treating depression with LSD

Psychedelic stock MindBio (CSE:MBIO) is revealing positive top-line data from its pioneering microdosing clinical trial to treat depression.

Clearmind Medicine to begin alcohol use disorder clinical trial

Clearmind Medicine (CSE:CMND) has received approval to begin its phase I/IIa clinical trial for alcohol use disorder in Israel.